Ridge Biotechnologies Emerges from Stealth with $25M Seed Funding for AI-Driven Enzyme Design Platform
核心洞察
Ridge Biotechnologies (搜索) emerged from stealth with an oversubscribed $25 million seed financing led by Sutter Hill Ventures (搜索) to advance AI-enabled enzyme and targeted drug design for precision medicines.
The company's platform uses proprietary machine learning models and high-throughput cell-free experimentation to generate up to a million-fold more sequence-function data than conventional methods for applications in ADCs, CAR-T therapies (搜索), and enzyme-based therapeutics.
Ridge Bio launched NativeLink (搜索) enzymes and ProTrigger (搜索) linkers as initial products, enabling site-specific protein modification and AI-designed protease-cleavable prodrug systems for improved therapeutic targeting.
Ridge Biotechnologies (搜索) emerged from stealth today with an oversubscribed $25 million seed financing round, positioning the company to advance its AI-driven platform for enzyme and targeted drug design across precision medicine applications. Sutter Hill Ventures (搜索), which incubated the company, led the financing with participation from Overlap Holdings (搜索) and other investors.
The Palo Alto-based company has developed a platform that combines proprietary machine learning models with high-throughput, cell-free experimentation to address applications spanning antibody-drug conjugates (搜索) (ADCs), in vivo CAR-T therapies (搜索), targeted nucleic acid delivery, small molecule biocatalysis, radiotherapies, and enzyme-based therapeutics.
Revolutionary Data Generation Capabilities
Ridge Bio's platform generates experimental datasets at unprecedented scale and speed, producing up to a million-fold more sequence-function data than conventional methods in a fraction of the time. This massive data generation capability powers custom-built machine learning models that enable enzyme and conditionally active drug design.
"Drug development should never be limited by the complexity of molecules we can precisely construct, off-target toxicities, or binding-based mechanisms of action," said Weston Kightlinger, PhD, co-founder and Chief Executive Officer of Ridge Bio. "Machine learning has dramatically expanded our ability to design enzymatic systems that can solve these problems, but unlocking their full potential requires massive experimental datasets."
Dr. Kightlinger, a serial entrepreneur and pioneer in cell-free synthesis and enzyme design, previously co-founded and served as Chief Technology Officer of SwiftScale Biologics (搜索), a cell-free manufacturing leader acquired by Resilience (搜索).
Initial Product Portfolio
Ridge Bio's initial offerings include two key product lines designed to advance next-generation bioconjugates. The NativeLink (搜索) enzymes are designer biocatalysts that enable drugmakers to site-specifically modify therapeutic proteins, augment them with diverse payloads, extend their half-lives, and add precision targeting systems without changing the protein sequence, cell lines, or upstream manufacturing processes.
The company's first product, the NativeLink-AXC enzyme (搜索), provides homogeneous modification of native antibodies without altering glycans, disulfide bonds, or amino acid sequences. This approach avoids stability, manufacturing, and functional challenges common with previous generations of ADC, antibody-oligonucleotide conjugate (搜索) (AOC), and other antibody conjugate synthesis strategies. The versatile system can achieve user-defined drug to antibody ratios (DARs) and multiple payloads, or even upgrade an existing ADC drug product directly into a dual payload ADC without additional process changes.
ProTrigger (搜索) linkers represent the company's second product line, featuring AI-designed protease-cleavable prodrug systems that release or activate therapeutic payloads at targeted sites in the body. Initial applications include unlocking new ADC targets, enhancing safety by reducing off-tumor toxicity, and targeting the tumor microenvironment and stroma.
Strategic Collaboration and Market Validation
Ridge Bio has announced a collaboration with a leading ADC-focused biotech company to leverage its ProTrigger (搜索) and NativeLink (搜索) product lines for designing and precisely attaching linker systems that deliver therapeutic payloads specifically to tumor tissue while sparing healthy cells.
"What used to take years can now be done in weeks, thanks to the combination of cell-free experimentation and machine learning," said Mike Jewett, Professor of Bioengineering at Stanford University and Ridge Bio's Academic Co-founder and Scientific Advisory Board Chair. "Together, they have created a step-change in our ability to design and leverage enzymes and prodrugs with exquisite specificity."
Distinguished Leadership and Advisory Network
The company's founding team combines expertise across machine learning-driven protein engineering, cell-free systems, and bioconjugation. The scientific team includes Grant Landwehr, PhD, who pioneered ML-accelerated cell-free enzyme engineering approaches at Stanford University; Antje Kruger, PhD, who launched cell-free enabled offerings for drug developers at Resilience (搜索); Francesca Li, PhD, who built AI-driven protein engineering methods at Caltech (搜索); and Josh Walker, PhD, who developed novel bioconjugation and ADC platforms at Bolt Therapeutics (搜索) and insitro (搜索).
Ridge Bio's advisory board features notable figures including 2022 Nobel Laureate in Chemistry Carolyn Bertozzi, PhD, from Stanford University; Sangeeta Bhatia, MD, PhD, from MIT/HHMI; and other distinguished experts in protein engineering and bioconjugation.
"Ridge Bio is at the forefront of three key trends: next-generation bioconjugates, protein design, and enzymatic therapeutics," said Dr. Bertozzi, whose work on biorthogonal chemistry earned her the Nobel Prize. "Their AI and experimental platform are very unique and it's already generating products that enable drug developers to differentiate themselves from competitors, not only through improved manufacturing but also through improved therapeutic indices while simultaneously unlocking the power of catalytic medicines."
Investment and Growth Strategy
Keith Loebner, PhD, Managing Director at Sutter Hill Ventures (搜索), emphasized the company's potential to address significant technical challenges in drug development. "Ridge Bio's capabilities across machine learning and wet lab bioengineering positions the company to build drugs that no one else can and enable a new class of precisely engineered enzyme-based therapeutics," he said.
Founded in 1962, Sutter Hill Ventures (搜索) has previously invested in and incubated companies including NVIDIA, Snowflake, PureStorage, Corcept Therapeutics, GRAIL, and Forty Seven.
With the seed funding, Ridge Bio plans to scale operations, expand technology partnerships in bioconjugates, and advance discovery programs toward developing a new class of precision-designed therapeutic enzymes. The company reports strong early interest from leading biopharma companies and contract development and manufacturing organizations (CDMOs), validating its approach to accelerating breakthrough medicine development.